Durata: 24 mesi (dal 01/09/2012 al 31/08/2014) Progetto n°: 01/2012 FFC Finanziato da: Fondazione per la Ricerca sulla Fibrosi Cistica-Bando 2012-Nonsense mutations are the leading cause of approximately 30% of inherited diseases, including cystic fibrosis (CF). They promote premature translational termination and following loss of CFTR protein by introduction of premature termination codons (PTCs). In the last few years, it has been demonstrated that drugs (like aminoglycoside antibiotics) can be designed and produced to suppress this process by the ribosomal read-through mechanism where these drugs mask PTC synthetizing a full-lengh CFTR protein. The rationale supporting of this project is to optimize the ribosomal read-through molecules leading to restoration of CFTR production in cystic fibrosis caused by stop mutation. This study may introduce new hopes for the development of a pharmacologic approach to the cure of CF.

L’approccio read-through per il trattamento della fibrosi cistica causata da mutazioni di stop Durata: 24 mesi (dal 01/09/2012 al 31/08/2014) Progetto n°: 01/2012 FFC Finanziato da: Fondazione per la Ricerca sulla Fibrosi Cistica-Bando 2012

BORGATTI, Monica
Primo
Funding Acquisition
;
2012

Abstract

Durata: 24 mesi (dal 01/09/2012 al 31/08/2014) Progetto n°: 01/2012 FFC Finanziato da: Fondazione per la Ricerca sulla Fibrosi Cistica-Bando 2012-Nonsense mutations are the leading cause of approximately 30% of inherited diseases, including cystic fibrosis (CF). They promote premature translational termination and following loss of CFTR protein by introduction of premature termination codons (PTCs). In the last few years, it has been demonstrated that drugs (like aminoglycoside antibiotics) can be designed and produced to suppress this process by the ribosomal read-through mechanism where these drugs mask PTC synthetizing a full-lengh CFTR protein. The rationale supporting of this project is to optimize the ribosomal read-through molecules leading to restoration of CFTR production in cystic fibrosis caused by stop mutation. This study may introduce new hopes for the development of a pharmacologic approach to the cure of CF.
2014
Finanziato da privati
Coordinatore
Nessun Finanziamento
Borgatti, Monica; Altamura, Nicola; Laufer, Ralph
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2360016
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact